A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Secukinumab (Primary) ; Secukinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms FUTURE 1 ext
- Sponsors Novartis
- 14 Feb 2018 This trial has been completed in Italy.
- 27 Jan 2018 This trial has been completed in Germany (End date: 2018-01-11).
- 26 Jan 2018 This trial has been completed in Bulgaria (End date: 2018-01-11).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History